These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8667603)

  • 21. Treatment of chronic hepatitis B (HBeAg-HBV DNA-positive) with lymphoblastoid alpha interferon with or without corticosteroids: short- and long-term follow-up.
    Zavaglia C; Bottelli R; Bellati G; Asti L; Mondazzi L; Iamoni G; Zanetti A; Tanzi E; Fesce E; Gelosa F; Maggi G; Ideo G
    Ital J Gastroenterol; 1996; 28(6):324-31. PubMed ID: 8891847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Semiquantitative anti-HBc IgM detection in children with chronic hepatitis B: a long-term follow-up study.
    Gaeta GB; Nardiello S; Pizzella T; Russo G; Maisto A; Sardaro C; Galanti B; Giusti G
    J Med Virol; 1995 Jul; 46(3):173-7. PubMed ID: 7561786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of hepatitis B virus populations in an interferon-alpha-treated patient reveals predominant mutations in the C-gene and changing e-antigenicity.
    Günther S; Paulij W; Meisel H; Will H
    Virology; 1998 Apr; 244(1):146-60. PubMed ID: 9581787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Response to interferon-alpha 2a in patients with e antigen-negative chronic hepatitis B.
    Kako M; Kanai K; Aikawa T; Iwabuchi S; Takehira Y; Kawasaki T; Tsubouchi H; Hino K; Tsuda F; Okamoto H; Miyakawa Y; Mayumi M
    J Clin Gastroenterol; 1997 Sep; 25(2):440-5. PubMed ID: 9412946
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Absence of hepatitis B virus precore mutants in patients with chronic hepatitis B responding to interferon-alpha.
    Xu J; Brown D; Harrison T; Lin Y; Dusheiko G
    Hepatology; 1992 Jun; 15(6):1002-6. PubMed ID: 1592338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of quantitative assays for hepatitis B e antigen and IgM antibody to hepatitis B core antigen to monitor therapy in chronic hepatitis B.
    Hayashi PH; Beames MP; Kuhns MC; Hoofnagle JH; Di Bisceglie AM
    Am J Gastroenterol; 1996 Nov; 91(11):2323-8. PubMed ID: 8931411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of granulocyte-macrophage colony-stimulating factor or lamivudine combination with recombinant interferon in non-responders to interferon in hepatitis B virus-related chronic liver disease patients.
    Guptan RC; Thakur V; Kazim SN; Sarin SK
    J Gastroenterol Hepatol; 2002 Jul; 17(7):765-71. PubMed ID: 12121506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term persistence of hepatitis B virus DNA in the serum of children with chronic hepatitis B after hepatitis B e antigen to antibody seroconversion.
    Bortolotti F; Wirth S; Crivellaro C; Alberti A; Martine U; de Moliner L
    J Pediatr Gastroenterol Nutr; 1996 Apr; 22(3):270-4. PubMed ID: 8708880
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis.
    Brunetto MR; Giarin MM; Oliveri F; Chiaberge E; Baldi M; Alfarano A; Serra A; Saracco G; Verme G; Will H
    Proc Natl Acad Sci U S A; 1991 May; 88(10):4186-90. PubMed ID: 2034663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Twelve-month interferon-alpha therapy induces a similar sustained response in anti-HBe-positive and HBeAg-positive chronic hepatitis B patients.
    Fernández I; Castellano G; Manzano ML; Colina F; Canga F; Muñoz R; Fuertes A; Solís JA
    Hepatogastroenterology; 2000; 47(35):1351-5. PubMed ID: 11100350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum.
    Lampertico P; Del Ninno E; Manzin A; Donato MF; Rumi MG; Lunghi G; Morabito A; Clementi M; Colombo M
    Hepatology; 1997 Dec; 26(6):1621-5. PubMed ID: 9398007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Precore wild-type DNA and immune complexes persist in chronic hepatitis B after seroconversion: no association between genome conversion and seroconversion.
    Maruyama T; Kuwata S; Koike K; Iino S; Yasuda K; Yotsuyanagi H; Moriya K; Maekawa H; Yamada H; Shibata Y; Milich DR
    Hepatology; 1998 Jan; 27(1):245-53. PubMed ID: 9425944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interferon treatment of anti-HBe positive and HBV DNA positive chronic hepatitis B.
    Alberti A; Fattovich G; Pontisso P; Brollo L; Belussi F; Ruol A
    Chemioterapia; 1988 Dec; 7 Suppl 3():15-9. PubMed ID: 3073869
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low frequency of precore hepatitis B virus mutants in anti-hepatitis B e-positive reactivation after loss of hepatitis B e antigen in patients with chronic hepatitis B.
    Loriot MA; Marcellin P; Talbodec N; Guigonis V; Gigou M; Boyer N; Bezeaud A; Erlinger S; Benhamou JP
    Hepatology; 1995 Mar; 21(3):627-31. PubMed ID: 7875659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.
    Perrillo RP; Lai CL; Liaw YF; Dienstag JL; Schiff ER; Schalm SW; Heathcote EJ; Brown NA; Atkins M; Woessner M; Gardner SD
    Hepatology; 2002 Jul; 36(1):186-94. PubMed ID: 12085364
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High rate of mutations in the hepatitis B core gene during the immune clearance phase of chronic hepatitis B virus infection.
    Bozkaya H; Ayola B; Lok AS
    Hepatology; 1996 Jul; 24(1):32-7. PubMed ID: 8707278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of peginterferon alpha-2a (40KD) in HBeAg-positive chronic hepatitis B patients.
    Caruntu FA; Streinu-Cercel A; Gheorghe LS; Grigorescu M; Sporea I; Stanciu C; Andronescu D; Voinea F; Diculescu M; Oproiu A; Voiosu R
    J Gastrointestin Liver Dis; 2009 Dec; 18(4):425-31. PubMed ID: 20076814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glomerulonephritis caused by chronic hepatitis B virus infection: treatment with recombinant human alpha-interferon.
    Lisker-Melman M; Webb D; Di Bisceglie AM; Kassianides C; Martin P; Rustgi V; Waggoner JG; Park Y; Hoofnagle JH
    Ann Intern Med; 1989 Sep; 111(6):479-83. PubMed ID: 2774373
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sequential analyses of the mutations in the core upstream and precore regions of hepatitis B virus genome in anti-HBe positive-carriers developing acute exacerbation.
    Nishizono A; Kohno K; Takita-Sonoda Y; Hiraga M; Terao H; Fujioka T; Nasu M; Mifune K
    J Med Virol; 1997 Nov; 53(3):266-72. PubMed ID: 9365894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histological improvement of chronic hepatitis B, and non-A, non-B with interferon treatment: application of a numerical scoring system for evaluating sequential morphologic changes.
    Okuno T; Shindo M; Arai K; Matsumoto M; Takeda M
    Gastroenterol Jpn; 1990 Feb; 25(1):70-7. PubMed ID: 2106467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.